JA Cohen

995 total citations · 1 hit paper
9 papers, 707 citations indexed

About

JA Cohen is a scholar working on Pathology and Forensic Medicine, Rheumatology and Oncology. According to data from OpenAlex, JA Cohen has authored 9 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 3 papers in Rheumatology and 2 papers in Oncology. Recurrent topics in JA Cohen's work include Multiple Sclerosis Research Studies (6 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and MRI in cancer diagnosis (1 paper). JA Cohen is often cited by papers focused on Multiple Sclerosis Research Studies (6 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and MRI in cancer diagnosis (1 paper). JA Cohen collaborates with scholars based in United States, Canada and United Kingdom. JA Cohen's co-authors include Ludwig Kappos, Michael Hutchinson, Massimo Filippi, Hillel Panitch, J Richert, Xavier Montalbán, Jun‐ichi Kira, Stephen C. Reingold, C.H. Polman and DH Miller and has published in prestigious journals such as Medicine & Science in Sports & Exercise, Journal of Neuroimmunology and Multiple Sclerosis Journal.

In The Last Decade

JA Cohen

9 papers receiving 672 citations

Hit Papers

Differential diagnosis of suspected multiple sclerosis: a... 2008 2026 2014 2020 2008 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
JA Cohen United States 6 562 309 182 122 78 9 707
Raed Behbehani Kuwait 18 508 0.9× 283 0.9× 155 0.9× 119 1.0× 76 1.0× 58 935
Luciana Midaglia Spain 16 687 1.2× 326 1.1× 178 1.0× 89 0.7× 113 1.4× 44 892
Damien Biotti France 15 287 0.5× 293 0.9× 95 0.5× 61 0.5× 55 0.7× 61 606
E. Mauch Germany 11 393 0.7× 251 0.8× 71 0.4× 71 0.6× 219 2.8× 27 603
J Richert United States 4 445 0.8× 263 0.9× 167 0.9× 69 0.6× 61 0.8× 5 515
T. Arbizu Spain 15 563 1.0× 216 0.7× 165 0.9× 118 1.0× 161 2.1× 28 745
Bertrand Bourre France 16 640 1.1× 461 1.5× 183 1.0× 50 0.4× 61 0.8× 41 782
Daniela Piani Meier Switzerland 12 379 0.7× 138 0.4× 104 0.6× 115 0.9× 61 0.8× 38 646
Mattias Vågberg Sweden 10 384 0.7× 230 0.7× 73 0.4× 64 0.5× 110 1.4× 14 617
Franz Felix Konen Germany 13 340 0.6× 181 0.6× 121 0.7× 82 0.7× 78 1.0× 42 509

Countries citing papers authored by JA Cohen

Since Specialization
Citations

This map shows the geographic impact of JA Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JA Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JA Cohen more than expected).

Fields of papers citing papers by JA Cohen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JA Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JA Cohen. The network helps show where JA Cohen may publish in the future.

Co-authorship network of co-authors of JA Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of JA Cohen. A scholar is included among the top collaborators of JA Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JA Cohen. JA Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Coles, Alasdair, JA Cohen, Gavin Giovannoni, et al.. (2017). Alemtuzumab CARE-MS II 5-year follow-up. Apollo (University of Cambridge). 6 indexed citations
2.
Francis, G., Ludwig Kappos, Paul O’Connor, et al.. (2013). Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Multiple Sclerosis Journal. 20(4). 471–480. 107 indexed citations
4.
Rudick, RA, CH Polman, JA Cohen, et al.. (2009). Assessing disability progression with the Multiple Sclerosis Functional Composite. Multiple Sclerosis Journal. 15(8). 984–997. 75 indexed citations
5.
Miller, DH, Massimo Filippi, JA Cohen, et al.. (2008). Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis Journal. 14(9). 1157–1174. 440 indexed citations breakdown →
6.
Cohen, JA, Peter A. Calabresi, Elizabeth Fisher, et al.. (2008). Avonex Combination Trial in relapsing—remitting MS: rationale, design and baseline data. Multiple Sclerosis Journal. 14(3). 370–382. 20 indexed citations
7.
Cohen, JA, R I Grossman, Supun Samarasekera, et al.. (1995). Assessment of the efficacy of copolymer-1 in the treatment of MS by quantitative MRI. Journal of Neuroimmunology. 56-63. 31–31. 3 indexed citations
8.
Constantinescu, Cris S., et al.. (1995). Clinical and subclinical neurological involvement in children of conjugal multiple sclerosis patients. Multiple Sclerosis Journal. 1(3). 170–172. 5 indexed citations
9.
Hayes, Peter, et al.. (1988). Sub-cutaneous fat thickness measured by magnetic resonance imaging, ultrasound, and calipers. Medicine & Science in Sports & Exercise. 20(3). 303–309. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026